Look no further than GlaxoSmithKline shedding its consumer ... and deliver far higher returns for shareholders, research finds. Building the new vision starts with defining a credible and meaningf ...

The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.40. The company’s shares opened today ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s shares opened today at p1,435.00. Leverage the ...

International drug giant GSK plc is moving its vaccine R&D and infectious disease teams to Cambridge from Maryland, and plans to expand its footprint here.

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside better-than-expected earnings for Q4 2025.

The company plans five new product approvals in 2025, including Blenrep for multiple myeloma and depemokimab for severe asthma. Specialty medicines accounted for more than 80% of GSK's growth in ...

GSK is moving out of its 635K SF footprint at 14200 Shady Grove Road, where it is the sole tenant, just before its lease ...

GSK has increased its long-term sales guidance amid hopes for a boost from new speciality medicines (Andy Buchanan/PA) Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales ...

If approved, the new presentation will offer a convenient administration option to healthcare professionals Globally, up to 1 in 3 adults will develop shingles in their lifetime 1,2,3,4 Over 25 ...

GSK said it expects core operating profits to rise by between 6% and 8% this year, with turnover set to lift by between 3% and 5%. It added that it expects further growth to be boosted by its strong ...